文献速递胸部肿瘤

戈沙妥珠单抗二线治疗广泛期小细胞肺癌的2期开放标签研究:TROPiCS-03结果

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.
PubMed 文献 · J Thorac Oncol · 2025-01-02

TROPiCS-03是一项2期开放标签篮子研究,评估戈沙妥珠单抗(SG)10 mg/kg在第1、8天给药(21天周期)用于既往接受过铂类化疗和抗PD-(L)1治疗后进展的广泛期小细胞肺癌(ES-SCLC)患者的疗效与安全性。43例患者中,研究者评估的客观缓解率(ORR)为41.9%(95%CI 27.0%-57.9%),中位缓解持续时间(DOR)、无进展生存期(PFS)和总生存期(OS)分别为4.73、4.40和13.60个月。结论认为SG在ES-SCLC二线治疗中显示出有前景的疗效,无论铂敏感状态如何,安全性可控且与其他SG研究一致。

要点

  • SG二线治疗ES-SCLC的ORR为41.9%(95%CI 27.0%-57.9%),18例确认部分缓解。
  • 中位DOR 4.73个月,中位PFS 4.40个月,中位OS 13.60个月。
  • 32例(74.4%)发生≥3级治疗中出现的不良事件,1例治疗相关不良事件(中性粒细胞减少性脓毒症)导致死亡。

核心结论

  • SG在ES-SCLC二线治疗中显示出有前景的疗效,无论铂敏感状态如何;安全性可控且与其他SG研究一致。

研究设计与样本

  • TROPiCS-03(NCT03964727)是一项多队列、开放标签、2期篮子研究,纳入实体瘤包括ES-SCLC。
  • 成人ES-SCLC患者在接受一线铂类化疗和抗PD-(L)1治疗后进展,接受SG 10 mg/kg在第1天和第8天给药,21天为一周期。
  • 主要终点为研究者根据RECIST 1.1评估的ORR;关键次要终点包括研究者评估的DOR和PFS、盲法独立中心评估的ORR、DOR和PFS、OS以及安全性。
  • 疗效在铂耐药和铂敏感疾病患者中分别评估。

主要发现

  • 43例患者(中位随访12.3个月,范围8.1-20.1个月)中,研究者评估的ORR为41.9%(95%CI 27.0%-57.9%),18例确认部分缓解。
  • 中位(95%CI)DOR为4.73(3.52-6.70)个月,PFS为4.40(3.81-6.11)个月,OS为13.60(6.57-14.78)个月。
  • 盲法独立中心评估的疗效结果与研究者评估相似。
  • 铂耐药疾病患者(n=20)研究者评估的ORR为35.0%(95%CI 15.4%-59.2%),铂敏感疾病患者(n=23)为47.8%(95%CI 26.8%-69.4%)。
  • 32例患者(74.4%)发生≥3级治疗中出现的不良事件(TEAE);无TEAE导致SG停药;1例治疗相关TEAE(中性粒细胞减少性脓毒症)导致死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase 2 TROPiCS-03 study evaluated the efficacy/safety of sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage SCLC (ES-SCLC). METHODS: TROPiCS-03 (NCT03964727) is a multicohort, open-label, phase 2 basket study of solid tumors, including ES-SCLC. Adults with ES-SCLC that progressed after one previous line of platinum-based chemotherapy and anti-programmed death-(ligand) 1 (PD-[L]1) therapy received SG 10 mg/kg on days 1 and 8 of a 21-day cycle. The primary end point was the investigator-assessed objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors version 1.1. Key secondary end points included investigator-assessed duration of response (DOR) and progression-free survival (PFS); blinded independent central review-assessed ORR, DOR, and PFS; overall survival (OS); and safety. Efficacy was evaluated in patients with platinum-resistant and platinum-sensitive disease. RESULTS: Among 43 patients (median follow-up, 12.3 [range, 8.1-20.1] mo), investigator-assessed ORR was 41.9% (95% confidence interval [CI]: 27.0%-57.9%), with 18 confirmed partial responses; median (95% CI) DOR, PFS, and OS were 4.73 (3.52-6.70), 4.40 (3.81-6.11), and 13.60 (6.57-14.78) months, respectively. The efficacy results of the blinded independent central review assessments were similar. The investigator-assessed ORR (95% CI) was 35.0% (15.4%-59.2%) in patients with platinum-resistant disease (n = 20) and 47.8% (26.8%-69.4%) in patients with platinum-sensitive disease (n = 23). Furthermore, 32 patients (74.4%) had grade greater than or equal to 3 treatment-emergent adverse events (TEAEs). No TEAE led to SG discontinuation; one treatment-related TEAE (neutropenic sepsis) led to death. CONCLUSIONS: SG has promising efficacy as second-line treatment of ES-SCLC, irrespective of platinum sensitivity. Safety was manageable and consistent with that observed in other SG studies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dowlati A, Chiang AC, Cervantes A, et al. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. J Thorac Oncol. 2025. PMID: 39755168. doi:10.1016/j.jtho.2024.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。